



November 10, 2023

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Chief Financial Officer
Toshiya Kitagawa
(TEL. 03-6214-3600)

GNI Group Completes Purchase of Elutia's Orthobiologics Business

GNI Group Co., Ltd. ("the Company"; "we", "the Group", including our subsidiaries and affiliates) today announced that due diligence, which was a prerequisite for closing the acquisition of a part of Elutia Inc.'s (Nasdaq listed ticker: ELUT; "Elutia") biologics business, was successfully completed, and the acquisition transaction has been closed.

The biomaterials business has recorded stable revenue and profits every year, and with this acquisition, 5 billion yen revenue for this business next year is now in sight. The acquisition is expected to increase our revenue in the United States and further expand and develop the Group's business in the United States.

1. Overview of acquisition transaction

(1) Board resolution date	September 17, 2023
(2) Contract conclusion date	September 17, 2023
(3) Due diligence completion date	2023 November
(4) Closing (business acquisition) date	November 9, 2023

2. Outline of accounting treatment

The accounting treatment of the new entity is being evaluated and will be disclosed when it is clear.

3. Outlook

This matter is not reflected in the revision to our 2023 full-year consolidated earnings forecast, which was disclosed on November 6, 2023. Upon thorough evaluation, we will promptly disclose any material matters should they arise.

About Elutia:

Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

About GNI Group Ltd.:

The Company is a holding company of global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below:

<https://www.gnipharma.com/>

This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. ("the Company"). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.